Angedonia in the structure of affective disorders: therapeutic opportunities

Close metadata

Recommended articles:

Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30

Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137

Sleep disorders and oncological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131

Pharmacogenomic and pharmacometabolomic biomarkers of the efficacy and safety of antidepressants: focus on selective serotonin reuptake inhibitors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):26-35

Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):43-47

Fluvoxamine in the treatment of anxiety-depressive spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):101-109

Antidepressants in psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):126-132

Melatonergic antidepressant agomelatine: augmentation of antipsychotic drugs in treatment of post-schizophrenic depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):5-12

Tolerability of multiphasic and monophasic combined hormonal contraceptives patients with uterine fibroids. Russian Journal of Human Reproduction. 2024;(4):78-89

Serotonin syndrome: focus on opioid analgesics. Russian Journal of Pain. 2024;(3):98-106

Anhedonia is one of the core features of depression. The article considers the place of anhedonia in the structure of affective disorders, its influence on the prognosis and effectiveness of therapy. The authors stress that various manifestations of anhedonia must be considered in correlation with the basic ability to feel pleasure. Therapy of anhedonia is not always effective. According to literature, agomelatin occupies a leading position among the drugs that reduce anhedonia.

Keywords:

anhedonia

affective disorders

depression

effectiveness of therapy

agomelatin

valdoxan

Authors:

Kasimova L.N.

Privolzhsky Research Medical University

Svyatogor M.V.

Privolzhsky Research Medical University

Received:

09.10.2019

Accepted:

15.10.2019

List of references:

World Health Organization, 2017. Depression and Other Common Mental Disorders: Global Health Estimates [Internet]. World Health Organization, Geneva, Switzerland.
Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. JAMA Psychiatry. 2015;72(6):603-611. https://doi.org/10.1001/jamapsychiatry.2015.0071
Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014. Sci Rep. 2018;8(1):2861. Published 2018 Feb 12. https://doi.org/10.1038/s41598-018-21243-x
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization; 1993.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
World Health Organization. World health statistics 2016: monitoring health for the SDGs sustainable development goals. World Health Organization, 2016.
Zimmerman M, Balling C, Chelminski I, Dalrymple K. Understanding the severity of depression: Which symptoms of depression are the best indicators of depression severity? Compr Psychiatry. 2018;87:84-88. https://doi.org/10.1016/j.comppsych.2018.09.006
Gao K, Sweet J, Su M, Calabrese JR. Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample. Asian J Psychiatr. 2017;27:40-47. https://doi.org/10.1016/j.ajp.2017.02.013
Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019;92:109-117. https://doi.org/10.1016/j.pnpbp.2019.01.002
Ducasse D, Loas G, Dassa D, Gramaglia C, Zeppegno P, Guillaume S, Courtet P. Anhedonia is associated with suicidal ideation independently of depression: A meta‐analysis. Depression and Anxiety. 2018;35(5):382-392. https://doi.org/10.1002/da.22709
Ho N, Sommers M. Anhedonia: a concept analysis. Arch Psychiatr Nurs. 2013;27(3):121-129. https://doi.org/10.1016/j.apnu.2013.02.001
Liu WH, Wang LZ, Shang HR, Shen Y, Li Z, Cheung EF, Chan RC. The influence of anhedonia on feedback negativity in major depressive disorder. Neuropsychologia. 2014;53:213-220. https://doi.org/10.1016/j.neuropsychologia.2013.11.023
Clark DC, Fawcett J, Salazar-Grueso E, Fawcett E. Seven-month clinical outcome of anhedonic and normally hedonic depressed inpatients. Am J Psychiatry. 1984;141(10):1216-1220. https://doi.org/10.1176/ajp.141.10.1216
Schrader GD. Does anhedonia correlate with depression severity in chronic depression? Compr Psychiatry. 1997;38(5):260-263. https://doi.org/10.1016/S0010-440X(97)90057-2
Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, Mors O, Elkin A, Williamson RJ, Schmael C, Henigsberg N, Perez J, Mendlewicz J, Janzing JGE, Zobel A, Skibinska M, Kozel D, Stamp AS, Bajs M, Placentino A, Barreto M, McGuffin P, Aitchison KJ. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychological Medicine. 2008;38(2):289-300. https://doi.org/10.1017/S0033291707001730
Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, McGuffin P. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: A secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) Study. The Journal of Clinical Psychiatry. 2011;72(11):1478-1484. https://doi.org/10.4088/JCP.10m06419
Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, Hauser J, Dernovsek MZ, Souery D, Bajs M, Maier W, Aitchison KJ, Farmer A, McGuffin P. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Medicine. 2012;42(5):967-980. https://doi.org/10.1017/S0033291711001905
McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, Wagner KD, Asarnow JR, Ryan ND, Birmaher B, Shamseddeen W, Mayes T, Kennard B, Spirito A, Keller M, Lynch FL, Dickerson JF, Brent DA. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012;51(4):404-411. https://doi.org/10.1016/j.jaac.2012.01.011
Vinckier F, Gourion D, Mouchabac S. Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur Psychiatry. 2017;44:1-8. https://doi.org/10.1016/j.eurpsy.2017.02.485
Rizvi SJ, Quilty LC, Sproule BA, Cyriac A, Bagby RM, Kennedy SH. Development and validation of the dimensional anhedonia rat-ing scale (DARS) in a community sample and individuals with major depression. Psychiatry Res. 2015;229(1-2):109-119. https://doi.org/10.1016/j.psychres.2015.07.062
Thomsen KR. Measuring anhedonia: impaired ability to pursue, experience, and learn about reward. Front Psychol. 2015;6:1409. https://doi.org/10.3389/fpsyg.2015.01409
Winer ES, Jordan DG, Collins AC. Conceptualizing anhedonias and implications for depression treatments. Psychol Res Behav Manag. 2019;12:325-335. https://doi.org/10.2147/PRBM.S159260
Stepanov IL. Anhedonia as a diagnostic, prognostic and maladaptive factor in various types of depression (phenomenology, dynamics, principles of therapy): Dis. ... d-ra med. nauk. M. 2004. (In Russ.).
Krylov VI. Anhedonia in disorders of the affective and schizophrenic spectrum: psychopathological features, diagnostic and prognostic value. Psikhiatriya i Psikhofarmakoterapiya im. P.B. Gannushkina. 2014;1:28-33. (In Russ.).
Shankman SA, Katz AC, DeLizza AA, Sarapas C, Gorka SM, Campbell ML. The different facets of anhedonia and their associations with different Psychopathologies. In: Ritsner MS, editor. Anhedonia: A Comprehensive Handbook Vol I. New York, NY: Springer; 2014. https://doi.org/10.1007/978-94-017-8591-4
Netter P, Hennig J. Discriminating depression, physical and social anhedonia by neurotransmitter related challenge tests. Psychology. 2016;7(03):275-285. https://doi.org/10.4236/psych.2016.73030
Olino TM, Horton LE, Versella MV. A comparison of psychometric and convergent validity for social anhedonia and social closeness. Psychol Assess. 2016;28(11):1465-1474. https://doi.org/10.1037/pas0000291
Klein D. Endogenomorphic depression. A conceptual and terminological revision. Arch Gen Psychiatry. 1974;31:447-454. https://doi.org/10.1001/archpsyc.1974.01760160005001
Fletcher K, Parker G, Paterson A, Fava M, Iosifescu D, Pizzagalli DA. Anhedonia in melancholic and non-melancholic depressive disorders. J Affect Disord. 2015;184:81-88. https://doi.org/10.1016/j.jad.2015.05.028
Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537-555. https://doi.org/10.1016/j.neubiorev.2010.06.006
Szczypiński JJ, Mateusz G. Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia? Reviews in the Neurosciences. 2017;29(7):727-744. https://doi.org/10.1515/revneuro-2017-0091
Treadway MT, Bossaller NA, Shelton RC, Zald DH. Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol. 2012;121(3):553-558. https://doi.org/10.1037/a0028813
Treadway MT. The Neurobiology of Motivational Deficits in Depression — An Update on Candidate Pathomechanisms. In: Simpson E, Balsam P. (eds) Behavioral Neuroscience of Motivation. Current Topics in Behavioral Neurosciences, vol 27. Springer. 2015;27:337-355. https://doi.org/10.1007/7854_2015_400
Yang XH, Huang J, Zhu CY, Wang YF, Cheung EF, Chan RC, Xie GR. Motivational deficits in effort-based decision making in individuals with subsyndromal depression, first-episode and remitted depression patients. Psychiatry Research. 2014;874-882. https://doi.org/10.1016/j.psychres.2014.08.056
Gard DE, Gard MG, Kring AM, John OP. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J Res Pers. 2006;40(6):1086-1102. https://doi.org/10.1016/j.jrp.2005.11.001
Baskin-Sommers AR, Foti D. Abnormal reward functioning across substance use disorders and major depressive disorder: Considering reward as a transdiagnostic mechanism. International Journal of Psychophysiology. 2015;98(2):227-239. https://doi.org/10.1016/j.ijpsycho.2015.01.011
Chen C, Takahashi T, Nakagawa S, Inoue T, Kusumi I. Reinforcement learning in depression: A review of computational research. Neurosci Biobehav Rev. 2015;55:247-267. https://doi.org/10.1016/j.neubiorev.2015.05.005
Whitton AE, Treadway MT, Pizzagalli DA. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry. 2015;28:7-12. https://doi.org/10.1097/YCO.0000000000000122
Bress JN, Hajcak G. Self-report and behavioral measures of reward sensitivity predict the feedback negativity. Psychophysiology. 2013;50:610-616. https://doi.org/10.1111/psyp.12053
Di Nicola M, De Risio L, Battaglia C, Camardese G, Tedeschi D, Mazza M, Martinotti G, Pozzi G, Niolu C, Di Giannantonio M, Siracusano A, Janiri L. Reduced hedonic capacity in euthymic bipolar subjects: A trait-like feature? Journal of Affective Disorders. 2013;147:446-450. https://doi.org/10.1016/j.jad.2012.10.004
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. https://doi.org/10.1001/2013.jamapsychiatry.4
Verdolini N, Dean J, Elisei S, Quartesan R, Zaman R, Agius M. Bipolar disorder: the importance of clinical assessment in identifying prognostic factors—an audit. Part 2: mixed state features and rapid cycling. Psychiatr Danub. 2014;26(1):301-308.
van Zessen R, Phillips JL, Budygin EA, Stuber GD. Activation of VTA GABA neurons disrupts reward consumption. Neuron. 2012;73(6):1184-1194. https://doi.org/10.1016/j.neuron.2012.02.016
Winer ES, Veilleux JC, Ginger EJ. Development and validation of the specific loss of interest and pleasure scale (SLIPS). J Affect Disord. 2014;152-154, 193-201. https://doi.org/10.1016/j.jad.2013.09.010
Winer ES, Nadorff MR, Ellis TE, Allen JG, Herrera S, Salem T. Anhedonia predicts suicidal ideation in a large psychiatric inpatient sample. Psychiatry Res. 2014;218(1-2):124-128. https://doi.org/10.1016/j.psychres.2014.04.016
Loas G. Anhedonia and risk of suicide: an overview Anhedonia: A Comprehensive Handbook Volume II. New York, NY: Springer; 2014. https://doi.org/10.1007/978-94-017-8591-4
Zielinski MJ, Veilleux JC, Winer ES, Nadorff MR. A short-term longitudinal examination of the relations between depression, anhedonia, and self-injurious thoughts and behaviors in adults with a history of self-injury. Compr Psychiatry. 2017;73:187-195. https://doi.org/10.1016/j.comppsych.2016.11.013
Corruble E, de Bodinat C, Belaidi C, Goodwin GM. Eﬃcacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16:2219-2234. https://doi.org/10.1017/S1461145713000679
Loas G, Lefebvre G, Rotsaert M, Englert Y. Relationships between anhedonia, suicidal ideation and suicide attempts in a large sample of physicians. PLoS One. 2018;13(3):e0193619. https://doi.org/10.1371/journal.pone.0193619
Blum K, Oscar-Berman M, Gardner EL, Simpatico T, Braverman ER, Gold MS. Neurogenetics and neurobiology of dopamine in anhedonia. In: Ritsner M.S., editor. Anhedonia: A Comprehensive Handbook. Vol. I. New York, NY: Springer; 2014. https://doi.org/10.1007/978-94-017-8591-4
Rolls ET, Grabenhorst F. The orbitofrontal cortex and beyond: from affect to decision-making. Prog Neurobiol. 2008;86(3):216-244. https://doi.org/10.1016/j.pneurobio.2008.09.001
Linnet J. Neurobiological underpinnings of reward anticipation and outcome evaluation in gambling disorder. Front Behav Neurosci. 2014;8:100. https://doi.org/10.3389/fnbeh.2014.00100
Treadway MT, Zald DH. Translational models of dopaminergic mechanisms for motivational deficits in anhedonic patients. In: Ritsner M.S., editor. Anhedonia: A Comprehensive Handbook vol I. New York, NY: Springer; 2014. https://doi.org/10.1007/978-94-017-8591-4
Padrao G, Mallorqui A, Cucurell D, Marco-Pallares J, Rodriguez-Fornells A. Neurophysiological differences in reward processing in anhedonics. Cogn Affect Behav Neurosci. 2013;13:102-115. https://doi.org/10.3758/s13415-012-0119-5
Thomsen KR, Whybrow PC, Kringelbach ML. Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain. Front Behav Neurosci. 2015;9:1-23. https://doi.org/10.3389/fnbeh.2015.00049
Salamone JD, Correa M, Yohn S, Lopez Cruz L, San Miguel N, Alatorre L. The pharmacology of effort-related choice behavior: dopamine, depression, and individual differences. Behav Process. 2016;127:3-17. https://doi.org/10.1016/j.beproc.2016.02.008
Deutschenbaur L, Beck J, Kiyhankhadiv A, Mühlhauser M, Borgwardt S, Walter M, Hasler G, Sollberger D, Lang UE. Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:325-333. https://doi.org/10.1016/j.pnpbp.2015.02.015
Rizvi SJ, Pizzagalli DA, Sproule BA, Kennedy SH. Assessing anhedonia in depression: potentials and pitfalls. Neurosci Biobehav Rev. 2016;65:21-35. https://doi.org/10.1016/j.neubiorev.2016.03.004
Barbano MF, Cador M. Opioids for hedonic experience and dopamine to get ready for it. Psychopharmacology. 2007;191(3):497-506. https://doi.org/10.1007/s00213-006-0521-1
Carlezon WA, Krystal AD. Kappa-opioid antagonists for psychiat-ric disorders: from bench to clinical trials. Depress Anxiety. 2016;33(10):895-906. https://doi.org/10.1002/da.22500
De Berardis D, Fornaro M, Orsolini L, Iasevoli F, Tomasetti C, de Bartolomeis A, Serroni N, De Lauretis I, Girinelli G, Mazza M, Valchera A, Carano A, Vellante F, Matarazzo I, Perna G, Martinotti G, Di Giannantonio M. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in «real-world», everyday clinical practice. CNS Spectrums. 2017;22(4):342-347. https://doi.org/10.1017/S1092852916000572
Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, Onofrj M, Janiri L, Di Giannantonio M. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012;32(4):487-491. https://doi.org/10.1097/JCP.0b013e31825d6c25
Burstein O, Franko M, Gale E, Handelsman A, Barak S, Motsan S, Shamir A, Toledano R, Simhon O, Hirshler Y, Chen G, Doron R. Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. PLoS ONE. 2017;12(11):e0188043. https://doi.org/10.1371/journal.pone.0188043
Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life sciences. 2018;210:177-184. https://doi.org/10.1016/j.lfs.2018.09.003
McIntyre RS, Gommoll C, Chen C, Ruth A. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. CNS Spectrums. 2016;21(5):385-392. https://doi.org/10.1017/S1092852915000899
Jouvent R, Le Houezec J, Payan C, Mikkelsen H, Fermanian J, Millet V, Dufour H. Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation. Psychiatry Res. 1998;79(3):267-275.
Lally N, Nugent AC, Luckenbaugh DA, Niciu M.J, Roiser JP, Zarate CA. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. Journal of Psychopharmacology. 2015;29(5):596-607. https://doi.org/10.1177/0269881114568041
Rizvi SJ, Geraci J, Ravindran A, Kennedy SH. Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue. J Clin Psychopharmacol. 2014;34(6):755-759. https://doi.org/10.1097/JCP.0000000000000211
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627. https://doi.org/10.1016/S2215-0366(16)30065-7

Close metadata